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Sir,
We agree with Dr Cappello’s comment relating to our paper
1
that the CD1a expression by dendritic cells (DC) in human cancers
is a very interesting observation and that the possible role of the
CD1a molecule in the presentation of tumour-associated antigens
requires further investigation. We were intrigued to note in the
Cappello et al paper
2 that CD1a was expressed in 75–94% of
epithelial biopsy tissue sections from patients with Barrett’s
metaplasia of the oesophagus, but that this was essentially not
found in patients with dysplasia or neoplasia, nor in normal gastric
or colonic tissues examined. Although the study was small, the
report brief, and did not contain more advanced invasive
carcinomas, it might indicate that transitory expression of CD1a
by epithelia may occur during the initial phases of carcinogenesis.
We have some unsubstantiated data that also indicate that some in
situ breast carcinomas may also show expression of CD1a. It is
unclear whether the expression of the CD1a molecules is actually
on the epithelial cells per se or on intraepithelial DC. We have
theorised that if CD1a expression occurs on both epithelial cells
and DC, then this may indicate a similar arrangement to that
observed for MHC molecular expression for presentation of
peptide antigens. This would strengthen our hypothesis that
CD1a, with some known structural similarity to MHC, may be very
important for the presentation of tumour-derived glycolipid
antigens to T cells. In addition, we are currently investigating
CD1a restricted T-cell responses against tumour antigens, and we
hypothesise that these are important for effective antitumour
immune responses in vivo. If epithelial cells in transition towards
neoplasia express CD1a together with neo-antigens, this may be a
sufficient ‘danger’ signal to alert the immune system to early
carcinogenesis, thus inducing an effective immune response in
some individuals – perhaps as a mechanism for epi-
thelial protection against further malignant progression. The
failure of expression of CD1a by epithelia in transition may not
allow an immune response to occur, perhaps explaining the
worse prognosis of CD1a-negative oesophageal lesions noted
in the study of Cappello et al. This theory remains to be
(dis)proved.
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